6th National Pharmaceutical Counsel's Forum

Fraud & Abuse in the Sales & Marketing of Drugs

Shaping Corporate Programs in Response to New Laws & Shifting Enforcement Priorities

Wednesday, October 11, 2006

About

With the federal government encouraging the states to develop their own diverse set of False Claims Acts, your client faces a whole new layer of compliance and enforcement. What's more, the practical impact of Medicare Part D is still unclear, as companies wrestle with the potential fraud and abuse consequences. Training and monitoring of sales reps continues to be a tricky issue, and the government is looking even more closely now at the fraud and abuse implications of educational programs.

With all these new challenges heaped on top of those that you've been facing for years, as well as the significant criminal and civil penalties affiliated with noncompliance, it is no wonder that federal, state, and global compliance remains a major unresolved issue. The risks are too great to rest on your laurels penalties can cost a company hundreds of millions of dollars, and enforcement actions can open the door to further risk of civil suits.

You need new and evolving strategies to stay ahead of the rapidly developing trends. The publication for American Conference Institute's Sixth National Forum on Fraud and Abuse in the Sales and Marketing of Drugs is a selection of presentations from industry experts that will provide you with the practical guidance that was presented at the conference. In-house counsel, training managers and compliance officers from companies such as Pfizer, FTI Consulting, Barr Laboratories, Bayer HealthCare, Sanofi Aventis, Medical Marketing Solutions LLC and Pacific Pulmonary Services provide frontline insights on creating and maintaining effective compliance policies and what steps you can take to minimize your company's exposure.

Contents & Contributors

About

With the federal government encouraging the states to develop their own diverse set of False Claims Acts, your client faces a whole new layer of compliance and enforcement. What's more, the practical impact of Medicare Part D is still unclear, as companies wrestle with the potential fraud and abuse consequences. Training and monitoring of sales reps continues to be a tricky issue, and the government is looking even more closely now at the fraud and abuse implications of educational programs.

With all these new challenges heaped on top of those that you've been facing for years, as well as the significant criminal and civil penalties affiliated with noncompliance, it is no wonder that federal, state, and global compliance remains a major unresolved issue. The risks are too great to rest on your laurels penalties can cost a company hundreds of millions of dollars, and enforcement actions can open the door to further risk of civil suits.

You need new and evolving strategies to stay ahead of the rapidly developing trends. The publication for American Conference Institute's Sixth National Forum on Fraud and Abuse in the Sales and Marketing of Drugs is a selection of presentations from industry experts that will provide you with the practical guidance that was presented at the conference. In-house counsel, training managers and compliance officers from companies such as Pfizer, FTI Consulting, Barr Laboratories, Bayer HealthCare, Sanofi Aventis, Medical Marketing Solutions LLC and Pacific Pulmonary Services provide frontline insights on creating and maintaining effective compliance policies and what steps you can take to minimize your company's exposure.

Contents & Contributors


NAVIGATING THE NEW STATE FALSE CLAIMS LANDSCAPE
Adam B. Siegel, Covington & Burling LLP

NAVIGATING THE NEW STATE FALSE CLAIMS LANDSCAPE
T. Reed Stephens, Sonnenschein Nath & Rosenthal LLP

DEVELOPING PREEMPTION ARGUMENTS: ARE YOU SAFE FROM STATE LAW CLAIMS?
Lana Varney, Fulbright & Jaworski L.L.P.
PLANNING FOR A RISE IN FEDERAL AND STATE QUI TAM LITIGATION & INCREASED WHISTLEBLOWER ACTIVITY
Jonathan Diesenhaus, Hogan & Hartson LLP
Michael C. Theis, Hogan & Hartson LLP

WHAT EVERY FRAUD AND ABUSE LAWYER MUST KNOW ABOUT BILLING AND COLLECTION
Larri Short, Arent Fox LLP

ANTICIPATING AND PREVENTING FRAUD & ABUSE ACTIONS BASED ON MEDICARE PART D
Kathleen H. McGuan, Centers for Medicare and Medicaid Services (CMS)
Robert J. Hill, Reed Smith LLP

LESSONS LEARNED FROM RECENT SETTLEMENT AGREEMENTS AND DECISIONS RE: SALE AND MARKETING OF DRUGS
Elizabeth I. Hack, Sonnenschein Nath & Rosenthal LLP

LESSONS LEARNED FROM RECENT SETTLEMENT AGREEMENTS AND DECISIONS RE: SALE AND MARKETING OF DRUGS
Ken Barker, FTI Consulting

EDUCATIONAL & RESEARCH ACTIVITIES: AVOIDING ALLEGATIONS OF KICKBACKS AND OFF-LABEL PROMOTION
Carolyn J. McElroy, Pacific Pulmonary Services
Michael L. Koon, Shook, Hardy & Bacon L.L.P.

SALES & MARKETING COMPLIANCE: FRAUD & ABUSE
William J. Van Nostrand, Medical Marketing Solutions, LLC

FOSTERING AND MONITORING COMPLIANCE BY FIELD-BASED SALES REPS
Donald O. Beers, Arnold & Porter LLP

RETAINING CUSTOMERS AS CONSULTANTS, SPEAKERS AND FAIR MARKET VALUATION, ETC.
Thomas D. Forrester, Sanofi-Aventis

DIRECTING NON-U.S. BASED OPERATIONS ON GLOBAL FRAUD & ABUSE RISKS
Gary Giampetruzzi, Pfizer

ETHICAL ISSUES/LEGAL CONSTRAINTS IN INVESTIGATIONS
John C. Dodds, Morgan, Lewis & Bockius LLP

MAKING DISCLOSURES: PRESERVING AND PROTECTING ATTORNEY-CLIENT INFORMATION WHEN OPERATING A COMPLIANCE DEPARTMENT
Robert S. Salcido, Akin Gump Strauss Hauer & Feld LLP

DEVELOPING A STATE-LAW COMPLIANCE PROGRAM UNDER THE DEFICIT REDUCTION ACT OF 2005
Trudy Seeley, Sanofi Aventis



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0